Cocrystal Pharma Inc (COCP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $18.88M
Last updated: Nov 17, 2026 at 10:48 AM ET
Cocrystal Pharma Inc (COCP) Stock Forecast
Analysts expect Cocrystal Pharma (COCP) to earn -$0.73 per share in the fiscal year ending Dec 31, 2026, on revenue of $110.00M. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.48.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.73
- EPS consensus, revenue $110.00M
- Fiscal year ending Dec 31, 2027
- -$0.48
- EPS consensus
- Next report
- Mar 29, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.73 | -$0.76 to -$0.69 | 2 | $110.00M | N/A | 3 |
| Dec 31, 2027 | -$0.48 | -$0.58 to -$0.37 | 2 | N/A | N/A | 2 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.15 | N/A | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.69.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.73 | -$0.69 | -$0.69 | -$0.69 | -$0.69 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.48 | -$0.58 | -$0.58 | -$0.64 | -$0.64 | N/A |
Frequently Asked Questions About COCP
What is the COCP stock forecast?
Consensus analyst estimates put Cocrystal Pharma's EPS at -$0.73 for the fiscal year ending Dec 31, 2026, on revenue of $110.00M.
What EPS do analysts expect from COCP next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.73, with estimates from -$0.76 to -$0.69 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.48, with estimates from -$0.58 to -$0.37 from 2 analysts.
What revenue do analysts expect from Cocrystal Pharma next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $110.00M.
How many analysts cover COCP?
2 analysts estimate EPS for Cocrystal Pharma for the fiscal year ending Dec 31, 2026.
COCP pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts